Immune checkpoint inhibitor induced large vessel vasculitis
Daisy Henderson, Gelareh Eslamian, Daniel Poon, Simon J. Crabb, Robert H. Jones, Peter Sankey, Bihani Kularatne, Mark Linch, Debra H. Josephs
Abstract
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
Topics & Concepts
NivolumabIpilimumabMedicineProstate cancerVasculitisImmune systemImmune checkpointInternal medicineCancerOncologyImmunologyImmunotherapyDiseaseCancer Immunotherapy and BiomarkersMultiple Myeloma Research and TreatmentsMelanoma and MAPK Pathways